Exelon shorts rebuild as Street trims targets

Exelon enters November with an interesting split between a strong one-month price recovery and a quietly rebuilding short position, two signals that rarely point in the same direction for a regulated utility.

The stock closed at $45.50 on November 3, up nearly 12% over the past month but down 2% on the day. That daily pullback came despite a 1.8% weekly gain, suggesting some profit-taking after the month's run. The next earnings date is not until February 10, so the near-term narrative is driven by positioning rather than a pending catalyst.

Short sellers have been adding exposure in a measured but consistent way. Short interest as a percentage of the free float has risen to 3.3%, up 6.4% week-on-week, with the position growing steadily from roughly 31.1 million shares in late October to 33.8 million by November 3. That is not a dramatic level for a large-cap utility, and borrow conditions remain comfortable. The cost to borrow has crept up around 11% over the past week to 0.51%, but that remains firmly in "low" territory. Availability is exceptionally loose at 1,849%, meaning there is vastly more stock available to borrow than is currently short, so there is no squeeze pressure in this lending market. The ORTEX short score has drifted upward to 38.5 over the past two weeks, its highest reading in that window, consistent with the gradual accumulation visible in the daily SI data.

Options positioning is calm and running slightly below its recent norm. The put/call ratio at 0.54 is just under its 20-day average of 0.56 and is half a standard deviation on the call-heavy side, well within normal for Exelon. The 52-week range on the PCR runs from 0.34 to 0.84, so current positioning is squarely in the middle. There is no sign of either elevated hedging demand or speculative call buying.

The Street view is cautious and has been moving in one direction. Morgan Stanley trimmed its target from $50 to $49 on October 21, maintaining Equal-Weight. JP Morgan also cut, moving from $47 to $46 on October 19 at Neutral. Barclays made the sharpest adjustment, dropping from $49 to $44 while holding Equal-Weight. Truist also lowered to $46 from $48. Against that tide, Keybanc upgraded to Sector Weight from Underweight on October 13, and HSBC initiated at Hold with a $44 target on October 22. The mean consensus target now sits at $47.76, implying modest upside from the current price. The forward earnings yield factor scores at the 60th percentile, and the 12-month forward EPS growth score ranks at the 82nd percentile, so there is genuine growth embedded in analyst models even as near-term targets drift lower. The bull case centres on Exelon's FERC transmission ROE of approximately 10.5% and the durability improvements in its Multi-Year Rate Plan construct. Bears point to rate case execution risk and a reduced capex outlook that could crimp the long-term growth trajectory.

BlackRock stands as the largest holder, reporting 119.8 million shares or 11.6% of outstanding stock as of September 30, having added 7 million shares in the most recent quarter. Capital Research and Management added 2.2 million shares to reach 60.4 million. These are passive and quasi-passive flows consistent with index weighting rather than active conviction, and no 13D activist positions appear on the register. Insider activity in the data is confined to routine director stock grants from March, all at the same size and price, with no open-market purchases or sales recorded in the past 90 days.

The last earnings print on October 30 produced a 1.2% next-day move, a mild reaction for a regulated utility. Peers moved similarly on the week: DUK gained 1.4%, SO 1.2%, and FE 2.0%, suggesting Exelon's 1.8% weekly gain is broadly in line with the sector rather than a stock-specific re-rating.

What to watch next is whether the steady rebuild in short interest continues through November ahead of the February earnings date, and whether the Street's pattern of incremental target reductions stabilises or extends as the regulatory calendar develops at ComEd and other operating subsidiaries.